Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
Open Access
- 1 July 1998
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 9 (7), 733-738
- https://doi.org/10.1023/a:1008286908930
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology, 1997
- GemcitabineDrugs, 1997
- In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabinBritish Journal of Cancer, 1997
- A role for paclitaxel in the combination chemotherapy of acute myeloblastic leukaemia: preclinical cell culture studiesBritish Journal of Haematology, 1996
- Clinical, toxicological and pharmacological aspects of gemcitabineCancer Treatment Reviews, 1996
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Cytotoxicity and Antitumor Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine)Cancer Investigation, 1990